Background: The prevalence of generalized anxiety disorder (GAD) represents an important public health issue. Hydroxyzine, an antagonist of histamine receptors, showed both efficacy and safety in previous short-term double-blind studies over placebo in this pathology. The aim of the current study was to confirm those positive results over a 3-month period in adult outpatients.
Method: This multicenter, parallel (hydroxyzine [50 mg/day]; bromazepam [6 mg/day]), randomized, double-blind, placebo-controlled trial included 2 weeks of single-blind run-in placebo, 12 weeks of double-blind randomized treatment, and 4 weeks of single-blind run-out placebo. Three hundred thirty-four of 369 selected outpatients with a diagnosis of GAD according to DSM-IV criteria and a Hamilton Rating Scale for Anxiety (HAM-A) total score >/= 20 were randomized before entering the double-blind period. The primary outcome criterion was the change in the HAM-A score from baseline to 12 weeks of double-blind treatment with hydroxyzine compared with placebo.
Results: In the intent-to-treat analysis, the mean +/- SD change in HAM-A scores from baseline to endpoint was -12.16 +/- 7.74 for hydroxyzine and -9.64 +/- 7.74 for placebo (p =.019). Results at endpoint for percentage of responders (p =.003) and remission rates (p =.028), Clinical Global Impressions-Severity scale score (p =.001), maintenance of efficacy (p =.022), and Hospital Anxiety and Depression scale score on day 84 (p =.008) also confirmed the efficacy of hydroxyzine over placebo. The study showed no statistically significant difference between hydroxyzine and bromazepam. Except for drowsiness, which was more frequent with bromazepam, safety results were comparable in the 3 groups.
Conclusion: Hydroxyzine showed both efficacy and safety in the treatment of GAD and appears to be an effective alternative treatment to benzodiazepine prescription.
Akhondzadeh S. Akhondzadeh S. Evid Based Ment Health. 2003 Aug;6(3):91. doi: 10.1136/ebmh.6.3.91. Evid Based Ment Health. 2003. PMID: 12893802 No abstract available.
Lader M, Scotto JC. Lader M, et al. Psychopharmacology (Berl). 1998 Oct;139(4):402-6. doi: 10.1007/s002130050731. Psychopharmacology (Berl). 1998. PMID: 9809861 Clinical Trial.
Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Gelenberg AJ, et al. JAMA. 2000 Jun 21;283(23):3082-8. doi: 10.1001/jama.283.23.3082. JAMA. 2000. PMID: 10865302 Clinical Trial.
Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J; Deramciclane Dose-Finding Study Group. Naukkarinen H, et al. Eur Neuropsychopharmacol. 2005 Dec;15(6):617-23. doi: 10.1016/j.euroneuro.2005.03.002. Epub 2005 Jun 9. Eur Neuropsychopharmacol. 2005. PMID: 15949921 Clinical Trial.
Ferreri M, Hantouche EG. Ferreri M, et al. Acta Psychiatr Scand Suppl. 1998;393:102-8. doi: 10.1111/j.1600-0447.1998.tb05974.x. Acta Psychiatr Scand Suppl. 1998. PMID: 9777055 Review.
Martiny K. Martiny K. Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.Munkholm K, Ussing A, Brink M, Edemann-Callesen H, Canbolat SS, Christensen R, Dahl KS, Ebdrup BH, Jensen MEJ, Kierulf-Lassen C, Madsen GK, Nielsen SM, Paulsen CP, Rohde JF, Tarp S, Baandrup L. Munkholm K, et al. Eur Arch Psychiatry Clin Neurosci. 2024 Apr;274(3):475-486. doi: 10.1007/s00406-023-01680-0. Epub 2023 Aug 25. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 37624378 Free PMC article.
Kim MJ, Kulkarni V, Goode MA, Sivesind TE. Kim MJ, et al. J Mol Graph Model. 2023 Nov;124:108539. doi: 10.1016/j.jmgm.2023.108539. Epub 2023 Jun 9. J Mol Graph Model. 2023. PMID: 37331258
Melaragno AJ. Melaragno AJ. Focus (Am Psychiatr Publ). 2021 Jun;19(2):145-160. doi: 10.1176/appi.focus.20200048. Epub 2021 Jun 17. Focus (Am Psychiatr Publ). 2021. PMID: 34690578 Free PMC article.
Parker EL, Banfield M, Fassnacht DB, Hatfield T, Kyrios M. Parker EL, et al. BMC Fam Pract. 2021 May 15;22(1):92. doi: 10.1186/s12875-021-01445-5. BMC Fam Pract. 2021. PMID: 33992082 Free PMC article.
Carl E, Witcraft SM, Kauffman BY, Gillespie EM, Becker ES, Cuijpers P, Van Ameringen M, Smits JAJ, Powers MB. Carl E, et al. Cogn Behav Ther. 2020 Jan;49(1):1-21. doi: 10.1080/16506073.2018.1560358. Epub 2019 Feb 14. Cogn Behav Ther. 2020. PMID: 30760112 Free PMC article.